|
Senate Engrossed
psilocybin services; regulation; licensure |
|
State of Arizona Senate Fifty-seventh Legislature First Regular Session 2025
|
|
SENATE BILL 1555 |
|
|
|
|
An Act
amending title 36, Arizona Revised Statutes, by adding chapter 42; relating to the department of health services.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Title 36, Arizona Revised Statutes, is amended by adding chapter 42, to read:
CHAPTER 42
PSILOCYBIN
ARTICLE 1. GENERAL PROVISIONS
36-4201. Arizona psilocybin advisory board; membership; terms; compensation
A. The Arizona psilocybin advisory board is established within the department consisting of not more than twelve members who are appointed as follows:
1. Four members appointed by the governor from the following:
(a) A representative of the department of health services.
(b) A representative of the Arizona health care cost containment system administration.
(c) A representative of the office of the attorney general.
(d) A representative of the department who is familiar with health care institution licensing.
(e) A person who is a professor or researcher at a university under the jurisdiction of the Arizona board of regents.
2. Four members appointed by the president of the senate from the following:
(a) An active member or a veteran of the United States armed forces.
(b) A person who is a law enforcement officer in this state.
(c) A person who represents firefighters in this state.
(d) A person who provides legal representation to and advocates on behalf of persons with mental illness or serious mental illness.
3. Four members appointed by the speaker of the house of representatives from the following:
(a) A psychologist who is licensed pursuant to title 32, chapter 19.1 and who has professional experience in DIAGNOSING or treating mental, emotional or behavioral conditions.
(b) A physician, preferably a psychiatrist, who is licensed pursuant to title 32, chapter 13 or 17 and who has experience in psychedelic-assisted therapy.
(c) A naturopathic physician who is licensed pursuant to title 32, chapter 14.
(d) A nurse practitioner who is licensed pursuant to title 32, chapter 15.
(e) A physician who is licensed pursuant to title 32, chapter 13 or 17 and who has expertise in addiction treatment.
(f) A physician who is licensed pursuant to title 32, chapter 13 or 17 and who has experience conducting clinical research involving the use of schedule I controlled substances.
B. On or before December 31, 2025, the governor, speaker of the house of representatives and president of the senate shall appoint the members of the board as specified in subsection A of this section.
C. On or before March 1, 2026, the board shall hold its first meeting at a time and place specified by the department.
D. Board members serve four-year terms. A board member is not eligible for reappointment once the person has been appointed for two full terms, in addition to any time served on the board to fill a vacancy. A person may be reappointed to the board after the person has not been on the board for a period of at least two full terms.
E. The board shall annually elect a chairperson from among its members.
F. The board shall meet at least once every two calendar months at a time and place determined by the chairperson or a majority of the voting members of the board.
G. Members of the board are not eligible to receive compensation but are eligible for reimbursement of expenses pursuant to title 38, chapter 4, article 2.
36-4202. Board; annual report
On or before July 31, 2026 and each July 31 thereafter, the board, in consultation with the department, shall publish and distribute to the public a report that includes a summary of:
1. Available medical, psychological and scientific studies, research and other information relating to the safety and efficacy of psilocybin in treating mental health conditions, including addiction, depression, anxiety disorders and end-of-life psychological distress.
2. Proposed and enacted laws,
regulations and policies regarding psilocybin by other policies
regarding psilocybin by other states or the federal government.